CLMT Stock Jumps As Revenue Beat Fuels Deleveraging Story

Calumet Inc. stocks have been trading up by 10.56 percent after announcing a major strategic expansion into renewable fuels.

Live Update At 12:33:22 EDT: On Monday, August 10, 2026 Calumet Inc stock [NASDAQ: CLMT] is trending up by 10.56%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

CLMT has been trading like a classic earnings momentum name. Over the last stretch of daily candles, Calumet Inc has pushed from the low $40s toward the mid-$40s, with the latest close around $43.66 after a strong intraday run. That puts CLMT well above the Goldman Sachs price target of $40, telling traders sentiment is already leaning optimistic.

On the fundamental side, CLMT reported Q2 revenue of $1.45B, beating the $1.12B FactSet consensus by a wide margin and up from $1.03B a year earlier. Earnings per share improved to -$1.09 from -$1.70, so the company is still losing money but bleeding less. Gross margin sits in the mid‑single digits and EBITDA margin is just 3.4%, which explains why net income is still negative at -$95.9M.

More Breaking News

• TEM Surges Into $1.5B MRD Deal As Stock Pulls Back
• ONDS Stock Gains Traction On Big Defense Contracts And AI Push
• ZJYL Stock Jumps Over 28% After Half-Year Results Ignite Trading
• XHLD Stock Whipsaws As Traders Target Volatile Move

The balance sheet is heavy. CLMT carries about $2.23B of long‑term debt, negative equity, and thin liquidity with a current ratio around 1. But operating cash flow of $92.3M and free cash flow of $54M in the quarter show the business is generating real cash, even with a net loss. For traders, that mix — high leverage, improving cash flow, and a revenue beat — often sets up volatile, directional moves.

Why Traders Are Watching CLMT After This Earnings Beat

Traders are locked in on CLMT because the story finally lines up: better numbers, cleaner balance sheet trends, and a visible growth project. The headline is simple. Calumet Specialty Products Partners delivered a big Q2 revenue beat at $1.45B, far above the $1.12B Wall Street expected, while also narrowing its loss. That combination usually gets momentum traders circling, and the recent push from sub‑$40 to the mid‑$40s backs that up on the tape.

Inside the quarter, CLMT highlighted strong specialty products margins, which are the higher‑value, less commodity‑driven part of the business. That matters. When the profitable segments carry the weight, every extra dollar of revenue has more punch. Management also called out $115M of debt reduction in July. In a company with negative equity and over $2B of long‑term debt, that kind of deleveraging is not a footnote — it is the core of the bull thesis.

Then there is Montana Renewables and the MaxSAF 150 capacity expansion. CLMT is framing this as a growth engine, tied to sustainable aviation fuel and energy transition demand. Traders do not need a PhD in refining to see the angle: if Montana Renewables scales and margins hold, CLMT’s earnings power in a few years could look very different from today’s -$1.09 EPS print.

Goldman Sachs nudging its CLMT price target up from $36 to $40, while staying Neutral, fits this picture. Big money is acknowledging progress, but not chasing the stock. For active traders, that gap between improving fundamentals and cautious coverage is fertile ground for short‑term momentum and sharp re‑ratings — in both directions.

Conclusion

CLMT is not a safe, sleepy name. This is a leveraged refiner and specialty products player trying to climb out of a deep hole, and the numbers show it. Profitability metrics are still negative, interest coverage is thin at 0.7, and working capital is underwater. That is why the stock can swing from the low $40s to the mid‑$40s in a single lively session as traders react to each new datapoint.

But the Q2 2026 print gave the bull case some real fuel. CLMT grew revenue to $1.45B, crushed consensus, narrowed its loss to -$1.09 per share, and threw off $54M of free cash flow. Management’s $115M July debt pay‑down and ongoing MaxSAF 150 expansion at Montana Renewables give a clear narrative: deleverage now, build earnings power for later. When a story gets that simple, day traders and swing traders tend to pile in.

The key is discipline. CLMT’s high debt load and negative equity mean any stumble — operational, macro, or project‑related — can hit the stock hard. As Tim Sykes likes to say, “The market doesn’t care about your opinion, only your risk management.” As Tim Bohen, lead trainer with StocksToTrade says, “The best trades are the ones you can make without emotion. Plan it, then execute it as if it’s routine.”. For traders studying CLMT, that means respecting the volatility, focusing on price action around catalysts like earnings and guidance, and cutting losses fast when the story or the chart starts to crack. This article is for educational and research purposes only, and each trader must make their own decisions and manage their own risk.

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

• How to Read Stock Charts: A Guide for Beginners
• Trading Plan: 6 Steps to Create One
• How To Create a Stock Watchlist

Ready to build your watchlists? Check out these curated lists:

• AI Penny Stocks
• Robinhood Penny Stocks
• Top Biotech Stocks

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.